Empagliflozin as Add-On to Metformin for 24 Weeks in Patients with Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2015
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Jun 2015 Results (pooled analysis of four, 24 week, phase III trials - NCT01159600, NCT01719003, NCT01778049, 3090558) presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
- 23 Jul 2013 New trial record
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.